Search hospitals > South Carolina > Charleston
Ralph H. Johnson VA Medical Center, Charleston, SC
Claim this profileCharleston, South Carolina 29401
Global Leader in Post-Traumatic Stress Disorder
Global Leader in Traumatic Stress Disorders
Conducts research for Stroke
Conducts research for Depression
Conducts research for Prostate Cancer
163 reported clinical trials
22 medical researchers
Summary
Ralph H. Johnson VA Medical Center, Charleston, SC is a medical facility located in Charleston, South Carolina. This center is recognized for care of Post-Traumatic Stress Disorder, Traumatic Stress Disorders, Stroke, Depression, Prostate Cancer and other specialties. Ralph H. Johnson VA Medical Center, Charleston, SC is involved with conducting 163 clinical trials across 161 conditions. There are 22 research doctors associated with this hospital, such as Oleksandra Lupak, Stephen J. Savage, Daniel F Gros, PhD MA BS, and Na Jin Seo, PhD MS BS.Top PIs
Oleksandra LupakRalph H Johnson VA Medical Center2 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
10 reported clinical trials
22 drugs studied
Stephen J. SavageRalph H Johnson VA Medical Center1 year of reported clinical research
Studies Prostate Cancer
Studies Bladder Cancer
7 reported clinical trials
10 drugs studied
Daniel F Gros, PhD MA BSRalph H. Johnson VA Medical Center, Charleston, SC3 years of reported clinical research
Studies Post-Traumatic Stress Disorder
Studies Depression
3 reported clinical trials
7 drugs studied
Na Jin Seo, PhD MS BSRalph H. Johnson VA Medical Center, Charleston, SC3 years of reported clinical research
Studies Stroke
3 reported clinical trials
5 drugs studied
Clinical Trials running at Ralph H. Johnson VA Medical Center, Charleston, SC
Bladder Cancer
Post-Traumatic Stress Disorder
Alzheimer's Disease
Depression
Lung Cancer
Multiple Myeloma
Stroke
Prostate Cancer
Sleep Disorders
Non-Small Cell Lung Cancer
Gemcitabine + Docetaxel vs BCG
for Bladder Cancer
This trial is testing whether a combination of two drugs, Gemcitabine and Docetaxel, given directly into the bladder, is effective for patients with high-grade non-muscle invasive bladder cancer who have not been treated with the standard therapy before. The goal is to see if this new treatment can prevent cancer from coming back or spreading. The study will also look at the quality of life, safety, and side effects of the new treatment. Gemcitabine and Docetaxel have shown promise as an alternative treatment, especially in cases where the standard therapy fails or is not tolerated.
Recruiting2 awards Phase 314 criteria
Pembrolizumab + Gemcitabine
for Bladder Cancer
This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment. Chemotherapy drugs, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the patient's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding pembrolizumab to gemcitabine may delay the return of BCG-unresponsive bladder cancer for longer period compared to gemcitabine alone.
Recruiting1 award Phase 223 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Ralph H. Johnson VA Medical Center, Charleston, SC?
Ralph H. Johnson VA Medical Center, Charleston, SC is a medical facility located in Charleston, South Carolina. This center is recognized for care of Post-Traumatic Stress Disorder, Traumatic Stress Disorders, Stroke, Depression, Prostate Cancer and other specialties. Ralph H. Johnson VA Medical Center, Charleston, SC is involved with conducting 163 clinical trials across 161 conditions. There are 22 research doctors associated with this hospital, such as Oleksandra Lupak, Stephen J. Savage, Daniel F Gros, PhD MA BS, and Na Jin Seo, PhD MS BS.